Raymond James & Associates Buys 20,397 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Raymond James & Associates boosted its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 2.5% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 820,771 shares of the medical research company’s stock after acquiring an additional 20,397 shares during the quarter. Raymond James & Associates owned approximately 0.45% of IQVIA worth $194,498,000 as of its most recent SEC filing.

A number of other hedge funds have also recently added to or reduced their stakes in the stock. First Foundation Advisors grew its holdings in IQVIA by 3.8% during the 2nd quarter. First Foundation Advisors now owns 1,161 shares of the medical research company’s stock worth $245,000 after acquiring an additional 43 shares during the last quarter. Team Hewins LLC lifted its position in IQVIA by 5.0% during the 1st quarter. Team Hewins LLC now owns 973 shares of the medical research company’s stock valued at $246,000 after purchasing an additional 46 shares during the period. Invera Wealth Advisors LLC lifted its position in IQVIA by 0.3% during the 2nd quarter. Invera Wealth Advisors LLC now owns 14,506 shares of the medical research company’s stock valued at $3,183,000 after purchasing an additional 46 shares during the period. Covestor Ltd lifted its position in IQVIA by 45.3% during the 1st quarter. Covestor Ltd now owns 154 shares of the medical research company’s stock valued at $39,000 after purchasing an additional 48 shares during the period. Finally, Oregon Public Employees Retirement Fund lifted its position in IQVIA by 0.3% during the 2nd quarter. Oregon Public Employees Retirement Fund now owns 15,668 shares of the medical research company’s stock valued at $3,313,000 after purchasing an additional 48 shares during the period. Institutional investors own 89.62% of the company’s stock.

IQVIA Stock Performance

NYSE IQV opened at $236.69 on Friday. The company has a current ratio of 0.85, a quick ratio of 0.85 and a debt-to-equity ratio of 1.80. The firm has a market capitalization of $43.15 billion, a price-to-earnings ratio of 30.74, a P/E/G ratio of 2.22 and a beta of 1.49. The firm’s 50 day simple moving average is $239.08 and its 200 day simple moving average is $231.16. IQVIA Holdings Inc. has a 1 year low of $167.42 and a 1 year high of $261.73.

IQVIA (NYSE:IQV) last issued its quarterly earnings data on Monday, July 22nd. The medical research company reported $2.64 EPS for the quarter, beating the consensus estimate of $2.57 by $0.07. The business had revenue of $3.81 billion during the quarter, compared to the consensus estimate of $3.79 billion. IQVIA had a net margin of 9.39% and a return on equity of 28.59%. The firm’s revenue was up 2.3% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $2.22 EPS. As a group, research analysts expect that IQVIA Holdings Inc. will post 10.25 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on IQV shares. StockNews.com upgraded shares of IQVIA from a “hold” rating to a “buy” rating in a research report on Monday, October 14th. Jefferies Financial Group downgraded shares of IQVIA from a “buy” rating to a “hold” rating and cut their price target for the company from $266.00 to $242.00 in a research report on Wednesday, July 24th. Royal Bank of Canada started coverage on shares of IQVIA in a research report on Wednesday, September 4th. They issued an “outperform” rating and a $275.00 price target on the stock. Evercore ISI cut their price target on shares of IQVIA from $270.00 to $265.00 and set an “outperform” rating on the stock in a research report on Tuesday, October 8th. Finally, UBS Group increased their target price on IQVIA from $295.00 to $300.00 and gave the stock a “buy” rating in a research note on Tuesday, July 23rd. Four research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $267.87.

Insider Activity

In other news, insider Eric Sherbet sold 1,300 shares of the firm’s stock in a transaction on Tuesday, August 27th. The shares were sold at an average price of $246.33, for a total transaction of $320,229.00. Following the completion of the transaction, the insider now owns 19,536 shares of the company’s stock, valued at approximately $4,812,302.88. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 1.60% of the company’s stock.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.